Comparing Patient Satisfaction With Pataday or Bepreve

NCT ID: NCT01450176

Last Updated: 2014-01-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2011-12-31

Brief Summary

The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1.5%) two times a day (BID).

Detailed Description

5 week randomized study with 15 subjects using Pataday qd for 2 weeks, and the other 15 subjects using Bepreve BID for 2 weeks. Following a one-week washout period, the two groups are given the opposite test article (TA) for 2 weeks. Subjects to complete daily diary regarding effects of drug and are seen in clinic for 3 exams.

Conditions

Eye Allergies

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pataday once daily

15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.

Group Type: ACTIVE_COMPARATOR

Olopatadine hydrochloride 0.2%

Intervention Type: DRUG

1 drop in each eye once daily for 2 weeks

Bepreve twice daily

Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks

Group Type: ACTIVE_COMPARATOR

Bepotastine besilate ophthalmic solution 1.5%

Intervention Type: DRUG

1 drop in each eye twice daily for 2 weeks

Interventions

Olopatadine hydrochloride 0.2%

1 drop in each eye once daily for 2 weeks

Intervention Type: DRUG

Bepotastine besilate ophthalmic solution 1.5%

1 drop in each eye twice daily for 2 weeks

Intervention Type: DRUG

Other Intervention Names

Pataday; Bepreve

Eligibility Criteria

Inclusion Criteria

• Be male or female subjects of any racial/ethnic group.
• Be at least 18 years of age or older.
• Have a diagnosis of allergic conjunctivitis with active symptoms, with no concurrent ocular allergy associated conditions and no plans to have ocular surgery during study period.
• Willing and able to return for all required visits and follow instructions from investigator and staff.
• Able to self-administer test article (TA) or have a caregiver available to instill all doses of TA.
• If a woman, capable of becoming pregnant, agrees to have pregnancy testing performed at screening (must be negative) and agrees to use a medically acceptable form of birth control (intrauterine device, birth control pill, patch or subcutaneous implant, condoms, diaphragm, and abstinence) throughout the study duration and for at least one week prior to and one week after completion of the study. Women considered capable of becoming pregnant include all females who have experienced menarche and who have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).
• Sign and date the informed consent form approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
• Be willing/able to return for all required study visits, to follow instructions from the study investigator and his/her staff, and to complete and return the Screening and Subject Diaries.

Exclusion Criteria

• Have known hypersensitivity to BEPREVE or PATADAY or any of their components.
• Are actively taking steroids or antihistamines during the study or within 7 days prior to enrolling in the study.
• Are pregnant, planning to become pregnant, or nursing/lactating.
• Have a known history of alcohol or drug abuse.
• Participated in a study of an investigational drug or device within the past 30 days prior to enrolling in the study.
• Have a presence of an active ocular infection (bacterial, viral or fungal), positive history of an ocular herpetic infection, or preauricular lymphadenopathy at any visit.
• Have any significant illness {eg: any autoimmune disease, or severe cardiovascular disease (including arrhythmias)}that the Investigator feels could be expected to interfere with the subject's safety or study parameters and/or put the subject at anyh unnecessary risk.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

McCabe Vision Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

McCabe Vision Center

Murfreesboro, Tennessee, United States

Countries

United States

Other Identifiers

3776-001

Identifier Type: REGISTRY

Identifier Source: secondary_id

MAC-04-11

Identifier Type: -

Identifier Source: org_study_id